 Jonathan Gutman
Concepts (317)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cord Blood Stem Cell Transplantation | 20 | 2024 | 99 | 6.190 |
Why?
| | Hematopoietic Stem Cell Transplantation | 21 | 2024 | 575 | 5.580 |
Why?
| | Leukemia, Myeloid, Acute | 25 | 2024 | 592 | 5.040 |
Why?
| | Graft vs Host Disease | 15 | 2024 | 239 | 4.260 |
Why?
| | Transplantation Conditioning | 16 | 2024 | 166 | 3.360 |
Why?
| | Azacitidine | 10 | 2024 | 139 | 2.460 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 12 | 2024 | 215 | 1.930 |
Why?
| | Sulfonamides | 11 | 2024 | 495 | 1.520 |
Why?
| | Hematologic Neoplasms | 6 | 2021 | 140 | 1.320 |
Why?
| | Transplantation, Haploidentical | 1 | 2024 | 21 | 0.910 |
Why?
| | Myelodysplastic Syndromes | 5 | 2019 | 129 | 0.860 |
Why?
| | Fetomaternal Transfusion | 1 | 2023 | 11 | 0.860 |
Why?
| | Cytomegalovirus Infections | 3 | 2023 | 186 | 0.830 |
Why?
| | Fetal Blood | 6 | 2022 | 317 | 0.820 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 1562 | 0.780 |
Why?
| | Recurrence | 10 | 2023 | 1004 | 0.760 |
Why?
| | Neoplasm, Residual | 5 | 2024 | 119 | 0.670 |
Why?
| | Leukemia | 5 | 2011 | 228 | 0.650 |
Why?
| | Transplantation, Homologous | 11 | 2023 | 389 | 0.610 |
Why?
| | Clostridium Infections | 1 | 2019 | 62 | 0.610 |
Why?
| | Vancomycin | 1 | 2019 | 78 | 0.600 |
Why?
| | Pregnancy Complications | 1 | 2023 | 491 | 0.600 |
Why?
| | Thiotepa | 1 | 2018 | 20 | 0.600 |
Why?
| | Retrospective Studies | 15 | 2024 | 14471 | 0.530 |
Why?
| | Humans | 71 | 2024 | 128495 | 0.520 |
Why?
| | Antineoplastic Agents | 6 | 2020 | 2042 | 0.500 |
Why?
| | Adult | 36 | 2024 | 35299 | 0.490 |
Why?
| | Stem Cell Transplantation | 4 | 2023 | 165 | 0.440 |
Why?
| | Middle Aged | 33 | 2024 | 30921 | 0.430 |
Why?
| | Carbon Monoxide | 1 | 2013 | 68 | 0.410 |
Why?
| | Blood Banks | 2 | 2012 | 40 | 0.390 |
Why?
| | CCAAT-Enhancer-Binding Protein-alpha | 1 | 2012 | 14 | 0.380 |
Why?
| | Hematopoietic Stem Cells | 3 | 2015 | 379 | 0.370 |
Why?
| | Blood Specimen Collection | 1 | 2011 | 34 | 0.370 |
Why?
| | Aged | 23 | 2024 | 21974 | 0.370 |
Why?
| | Germ-Line Mutation | 1 | 2012 | 138 | 0.360 |
Why?
| | HLA Antigens | 4 | 2019 | 234 | 0.360 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2017 | 227 | 0.350 |
Why?
| | Hemoglobins | 1 | 2013 | 337 | 0.350 |
Why?
| | Lymphoma | 2 | 2017 | 195 | 0.350 |
Why?
| | Young Adult | 13 | 2024 | 12349 | 0.340 |
Why?
| | Female | 38 | 2024 | 68266 | 0.340 |
Why?
| | Whole-Body Irradiation | 5 | 2019 | 76 | 0.330 |
Why?
| | Cesarean Section | 1 | 2011 | 182 | 0.330 |
Why?
| | Graft vs Leukemia Effect | 1 | 2009 | 12 | 0.330 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1705 | 0.310 |
Why?
| | Treatment Outcome | 13 | 2024 | 10162 | 0.310 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2023 | 958 | 0.300 |
Why?
| | Pulmonary Veno-Occlusive Disease | 1 | 2008 | 10 | 0.300 |
Why?
| | Isoantibodies | 1 | 2009 | 51 | 0.300 |
Why?
| | Male | 38 | 2024 | 63043 | 0.300 |
Why?
| | Neoplastic Stem Cells | 3 | 2018 | 380 | 0.300 |
Why?
| | Disease-Free Survival | 4 | 2022 | 647 | 0.280 |
Why?
| | Rhinovirus | 1 | 2007 | 56 | 0.270 |
Why?
| | Picornaviridae Infections | 1 | 2007 | 45 | 0.270 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2013 | 112 | 0.270 |
Why?
| | Graft Rejection | 2 | 2012 | 557 | 0.270 |
Why?
| | Vidarabine | 2 | 2018 | 30 | 0.260 |
Why?
| | Altitude Sickness | 4 | 2008 | 137 | 0.250 |
Why?
| | Clonal Evolution | 2 | 2017 | 39 | 0.250 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2020 | 749 | 0.250 |
Why?
| | Prognosis | 7 | 2024 | 3780 | 0.230 |
Why?
| | Chronic Disease | 3 | 2022 | 1692 | 0.230 |
Why?
| | Histocompatibility Testing | 3 | 2016 | 120 | 0.230 |
Why?
| | Mutation | 3 | 2024 | 3696 | 0.220 |
Why?
| | Immune Reconstitution | 1 | 2023 | 6 | 0.210 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2009 | 842 | 0.210 |
Why?
| | Altitude | 5 | 2007 | 452 | 0.210 |
Why?
| | Living Donors | 1 | 2005 | 287 | 0.210 |
Why?
| | Respiratory Tract Infections | 1 | 2007 | 372 | 0.210 |
Why?
| | Adolescent | 11 | 2024 | 20304 | 0.200 |
Why?
| | Unrelated Donors | 3 | 2021 | 36 | 0.200 |
Why?
| | Pulmonary Edema | 3 | 2007 | 104 | 0.200 |
Why?
| | Carrier Proteins | 2 | 2017 | 732 | 0.190 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2017 | 758 | 0.190 |
Why?
| | Nuclear Proteins | 2 | 2017 | 658 | 0.180 |
Why?
| | Siblings | 1 | 2022 | 215 | 0.180 |
Why?
| | Chimerism | 1 | 2021 | 29 | 0.180 |
Why?
| | Salvage Therapy | 2 | 2019 | 134 | 0.180 |
Why?
| | Allografts | 1 | 2021 | 136 | 0.180 |
Why?
| | Myeloablative Agonists | 2 | 2018 | 21 | 0.180 |
Why?
| | Sirolimus | 2 | 2019 | 190 | 0.180 |
Why?
| | Stem Cells | 2 | 2015 | 578 | 0.170 |
Why?
| | Antibodies, Monoclonal | 2 | 2017 | 1357 | 0.170 |
Why?
| | Survival Analysis | 3 | 2018 | 1265 | 0.170 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 1 | 2019 | 17 | 0.160 |
Why?
| | Relaxation Therapy | 1 | 2019 | 17 | 0.160 |
Why?
| | Leukocytes | 1 | 2021 | 303 | 0.160 |
Why?
| | Breathing Exercises | 1 | 2019 | 20 | 0.160 |
Why?
| | Decision Support Systems, Clinical | 1 | 2022 | 205 | 0.160 |
Why?
| | Antiviral Agents | 3 | 2023 | 711 | 0.160 |
Why?
| | Acetates | 1 | 2019 | 99 | 0.160 |
Why?
| | Quality of Life | 2 | 2022 | 2688 | 0.160 |
Why?
| | Busulfan | 2 | 2020 | 15 | 0.150 |
Why?
| | Mycophenolic Acid | 1 | 2019 | 89 | 0.150 |
Why?
| | Fetus | 1 | 2023 | 765 | 0.150 |
Why?
| | Mountaineering | 3 | 2008 | 34 | 0.150 |
Why?
| | Cyclosporine | 1 | 2019 | 171 | 0.150 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2013 | 278 | 0.150 |
Why?
| | Quinazolines | 1 | 2019 | 243 | 0.150 |
Why?
| | Socioeconomic Factors | 1 | 2022 | 1212 | 0.140 |
Why?
| | Optic Nerve | 2 | 2008 | 64 | 0.140 |
Why?
| | Psychotherapy | 1 | 2019 | 155 | 0.140 |
Why?
| | Intracranial Pressure | 2 | 2008 | 45 | 0.140 |
Why?
| | Leukemia, Neutrophilic, Chronic | 1 | 2017 | 5 | 0.140 |
Why?
| | Receptors, Colony-Stimulating Factor | 1 | 2017 | 6 | 0.140 |
Why?
| | Mediastinal Neoplasms | 1 | 2017 | 38 | 0.140 |
Why?
| | Immunosuppressive Agents | 2 | 2019 | 684 | 0.140 |
Why?
| | Administration, Oral | 1 | 2019 | 767 | 0.140 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2016 | 50 | 0.130 |
Why?
| | Myelin Sheath | 2 | 2008 | 161 | 0.130 |
Why?
| | Pregnancy | 2 | 2023 | 6373 | 0.130 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2016 | 67 | 0.130 |
Why?
| | Aged, 80 and over | 7 | 2024 | 7057 | 0.130 |
Why?
| | Immunotherapy, Adoptive | 1 | 2019 | 296 | 0.130 |
Why?
| | Adipocytes, White | 1 | 2015 | 17 | 0.130 |
Why?
| | Neoplasms, Plasma Cell | 1 | 2015 | 7 | 0.130 |
Why?
| | Leukocytosis | 1 | 2015 | 32 | 0.120 |
Why?
| | Child | 8 | 2024 | 20805 | 0.120 |
Why?
| | Gene Frequency | 1 | 2017 | 504 | 0.120 |
Why?
| | Hodgkin Disease | 1 | 2017 | 134 | 0.120 |
Why?
| | Pulmonary Diffusing Capacity | 2 | 2013 | 74 | 0.120 |
Why?
| | Computational Biology | 1 | 2019 | 597 | 0.110 |
Why?
| | Dalteparin | 1 | 2014 | 10 | 0.110 |
Why?
| | Incidence | 3 | 2016 | 2638 | 0.110 |
Why?
| | Respiratory Function Tests | 2 | 2013 | 580 | 0.110 |
Why?
| | Harringtonines | 1 | 2013 | 2 | 0.110 |
Why?
| | Pyrazoles | 1 | 2017 | 404 | 0.110 |
Why?
| | Transplantation Chimera | 2 | 2012 | 54 | 0.110 |
Why?
| | Neoplasm Proteins | 1 | 2016 | 420 | 0.100 |
Why?
| | Antilymphocyte Serum | 1 | 2012 | 63 | 0.100 |
Why?
| | Pyridazines | 1 | 2013 | 51 | 0.100 |
Why?
| | Induction Chemotherapy | 2 | 2024 | 70 | 0.100 |
Why?
| | Receptors, CCR5 | 1 | 2012 | 57 | 0.100 |
Why?
| | Bone Marrow | 3 | 2021 | 267 | 0.100 |
Why?
| | Thrombocytopenia | 1 | 2014 | 185 | 0.100 |
Why?
| | Neoplasms | 2 | 2019 | 2463 | 0.100 |
Why?
| | Remission Induction | 3 | 2019 | 268 | 0.100 |
Why?
| | Sequence Deletion | 1 | 2012 | 178 | 0.100 |
Why?
| | Imidazoles | 1 | 2013 | 229 | 0.100 |
Why?
| | Caregivers | 1 | 2019 | 813 | 0.090 |
Why?
| | Hematopoiesis | 2 | 2010 | 185 | 0.090 |
Why?
| | Fibrinolytic Agents | 1 | 2014 | 261 | 0.090 |
Why?
| | Lung Diseases | 2 | 2011 | 715 | 0.090 |
Why?
| | Ganciclovir | 1 | 2011 | 51 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 1 | 2014 | 636 | 0.090 |
Why?
| | Adipose Tissue | 1 | 2015 | 589 | 0.090 |
Why?
| | Drug Delivery Systems | 1 | 2014 | 327 | 0.090 |
Why?
| | Risk Factors | 3 | 2014 | 9737 | 0.090 |
Why?
| | Stress, Psychological | 1 | 2019 | 1064 | 0.090 |
Why?
| | Length of Stay | 1 | 2016 | 1119 | 0.090 |
Why?
| | Thrombosis | 1 | 2014 | 343 | 0.090 |
Why?
| | Pedigree | 1 | 2012 | 485 | 0.090 |
Why?
| | Immunologic Factors | 1 | 2012 | 231 | 0.090 |
Why?
| | Acute Disease | 2 | 2012 | 965 | 0.090 |
Why?
| | Blood Donors | 1 | 2011 | 96 | 0.090 |
Why?
| | Leukocyte Count | 2 | 2024 | 326 | 0.080 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2016 | 1045 | 0.080 |
Why?
| | Umbilical Cord | 1 | 2010 | 84 | 0.080 |
Why?
| | Neutrophils | 1 | 2015 | 1192 | 0.080 |
Why?
| | Cell Differentiation | 3 | 2015 | 1900 | 0.080 |
Why?
| | Leukocytes, Mononuclear | 1 | 2012 | 539 | 0.080 |
Why?
| | Polymerase Chain Reaction | 2 | 2024 | 1027 | 0.080 |
Why?
| | Treatment Failure | 2 | 2009 | 338 | 0.080 |
Why?
| | Opportunistic Infections | 1 | 2009 | 46 | 0.080 |
Why?
| | Mycosis Fungoides | 1 | 2009 | 63 | 0.080 |
Why?
| | Infant | 4 | 2014 | 9001 | 0.070 |
Why?
| | Prednisolone | 1 | 2008 | 82 | 0.070 |
Why?
| | Comorbidity | 1 | 2013 | 1541 | 0.070 |
Why?
| | Nepal | 4 | 2008 | 22 | 0.070 |
Why?
| | Child, Preschool | 4 | 2014 | 10487 | 0.070 |
Why?
| | Warfarin | 1 | 2008 | 145 | 0.070 |
Why?
| | Family | 1 | 2012 | 649 | 0.070 |
Why?
| | Cell Proliferation | 1 | 2014 | 2345 | 0.070 |
Why?
| | Monitoring, Physiologic | 1 | 2009 | 264 | 0.070 |
Why?
| | Heparin | 1 | 2008 | 253 | 0.070 |
Why?
| | Fatal Outcome | 1 | 2007 | 301 | 0.070 |
Why?
| | Intracranial Hypertension | 1 | 2007 | 37 | 0.070 |
Why?
| | Mice, SCID | 2 | 2019 | 350 | 0.060 |
Why?
| | Interferon-gamma | 1 | 2009 | 761 | 0.060 |
Why?
| | Follow-Up Studies | 5 | 2019 | 4874 | 0.060 |
Why?
| | Algorithms | 3 | 2009 | 1614 | 0.060 |
Why?
| | Thromboembolism | 1 | 2007 | 111 | 0.060 |
Why?
| | Emergency Treatment | 1 | 2007 | 113 | 0.060 |
Why?
| | Flow Cytometry | 1 | 2009 | 1142 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2018 | 229 | 0.060 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2007 | 141 | 0.060 |
Why?
| | Mice, Inbred NOD | 2 | 2019 | 586 | 0.060 |
Why?
| | Vasodilator Agents | 1 | 2007 | 324 | 0.060 |
Why?
| | Anti-Inflammatory Agents | 1 | 2008 | 470 | 0.060 |
Why?
| | Transplantation, Autologous | 1 | 2005 | 211 | 0.060 |
Why?
| | Syphilis, Cutaneous | 1 | 2004 | 3 | 0.060 |
Why?
| | Survival Rate | 2 | 2019 | 1871 | 0.060 |
Why?
| | Treponema pallidum | 1 | 2004 | 8 | 0.060 |
Why?
| | Sensitivity and Specificity | 1 | 2009 | 1817 | 0.060 |
Why?
| | Anticoagulants | 1 | 2008 | 634 | 0.050 |
Why?
| | Anxiety Disorders | 1 | 2007 | 351 | 0.050 |
Why?
| | Cohort Studies | 2 | 2011 | 5402 | 0.050 |
Why?
| | Proportional Hazards Models | 2 | 2019 | 1200 | 0.050 |
Why?
| | Cytomegalovirus | 1 | 2023 | 152 | 0.050 |
Why?
| | Drug Interactions | 2 | 2013 | 361 | 0.050 |
Why?
| | Transplant Recipients | 1 | 2023 | 153 | 0.050 |
Why?
| | Sialic Acid Binding Ig-like Lectin 3 | 1 | 2021 | 9 | 0.050 |
Why?
| | Blood Grouping and Crossmatching | 1 | 2021 | 14 | 0.050 |
Why?
| | CD56 Antigen | 1 | 2021 | 37 | 0.050 |
Why?
| | CD3 Complex | 1 | 2021 | 101 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 2 | 2007 | 2517 | 0.040 |
Why?
| | Phenylurea Compounds | 1 | 2020 | 89 | 0.040 |
Why?
| | Ultrasonography | 3 | 2008 | 712 | 0.040 |
Why?
| | Clubfoot | 1 | 1999 | 5 | 0.040 |
Why?
| | Tarsal Bones | 1 | 1999 | 13 | 0.040 |
Why?
| | Lentivirus | 1 | 2019 | 52 | 0.040 |
Why?
| | Benzimidazoles | 1 | 2020 | 160 | 0.040 |
Why?
| | Calcaneus | 1 | 1999 | 31 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 2 | 2017 | 880 | 0.040 |
Why?
| | Clinical Trials as Topic | 2 | 2014 | 1003 | 0.040 |
Why?
| | Tricarboxylic Acids | 1 | 2018 | 10 | 0.040 |
Why?
| | Ketoglutaric Acids | 1 | 2018 | 15 | 0.040 |
Why?
| | Electron Transport Complex II | 1 | 2018 | 24 | 0.040 |
Why?
| | Genes, myc | 1 | 1998 | 50 | 0.040 |
Why?
| | Succinate Dehydrogenase | 1 | 2018 | 43 | 0.040 |
Why?
| | Gene Targeting | 1 | 1998 | 82 | 0.040 |
Why?
| | Tendons | 1 | 1999 | 106 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2020 | 260 | 0.040 |
Why?
| | Acetazolamide | 2 | 2008 | 24 | 0.040 |
Why?
| | Oxidative Phosphorylation | 1 | 2018 | 186 | 0.040 |
Why?
| | Machine Learning | 1 | 2022 | 444 | 0.030 |
Why?
| | Orthopedic Procedures | 1 | 1999 | 207 | 0.030 |
Why?
| | NADP | 1 | 2016 | 43 | 0.030 |
Why?
| | Genetic Testing | 1 | 2019 | 428 | 0.030 |
Why?
| | Deoxyglucose | 1 | 2016 | 49 | 0.030 |
Why?
| | Sesquiterpenes | 1 | 2016 | 52 | 0.030 |
Why?
| | Nitriles | 1 | 2017 | 160 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2019 | 1016 | 0.030 |
Why?
| | Cell Fusion | 1 | 2015 | 51 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2014 | 4017 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 283 | 0.030 |
Why?
| | Prospective Studies | 2 | 2020 | 7069 | 0.030 |
Why?
| | Chromosome Aberrations | 1 | 2015 | 149 | 0.030 |
Why?
| | Animals | 5 | 2019 | 34647 | 0.030 |
Why?
| | Interleukin Receptor Common gamma Subunit | 1 | 2014 | 14 | 0.030 |
Why?
| | Severity of Illness Index | 3 | 2007 | 2719 | 0.030 |
Why?
| | Bone Marrow Cells | 1 | 2015 | 293 | 0.030 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2015 | 313 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 385 | 0.030 |
Why?
| | Mortality | 1 | 2016 | 306 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2016 | 409 | 0.030 |
Why?
| | Cell Lineage | 1 | 2015 | 336 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 1938 | 0.030 |
Why?
| | Pyrimidines | 1 | 2017 | 449 | 0.030 |
Why?
| | Up-Regulation | 1 | 2016 | 823 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2014 | 130 | 0.030 |
Why?
| | Philadelphia Chromosome | 1 | 2013 | 18 | 0.030 |
Why?
| | Bone Marrow Transplantation | 1 | 2014 | 269 | 0.030 |
Why?
| | Energy Metabolism | 1 | 2018 | 833 | 0.030 |
Why?
| | Survivors | 1 | 2016 | 462 | 0.030 |
Why?
| | Mice | 3 | 2019 | 16620 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2014 | 345 | 0.020 |
Why?
| | Gene Expression | 1 | 2017 | 1455 | 0.020 |
Why?
| | Biopsy | 1 | 2015 | 1079 | 0.020 |
Why?
| | Blood Transfusion | 1 | 2014 | 295 | 0.020 |
Why?
| | DNA | 1 | 1998 | 1394 | 0.020 |
Why?
| | Probability | 1 | 2012 | 306 | 0.020 |
Why?
| | Cryopreservation | 1 | 2012 | 97 | 0.020 |
Why?
| | Hospitalization | 2 | 2014 | 2069 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 1998 | 1423 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2011 | 156 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2015 | 1199 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2015 | 2069 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2011 | 219 | 0.020 |
Why?
| | Apoptosis | 1 | 2018 | 2437 | 0.020 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2013 | 431 | 0.020 |
Why?
| | Viral Load | 1 | 2011 | 449 | 0.020 |
Why?
| | Disease Progression | 1 | 2017 | 2604 | 0.020 |
Why?
| | Carbonic Anhydrase Inhibitors | 1 | 2008 | 14 | 0.020 |
Why?
| | Donor Selection | 1 | 2009 | 75 | 0.020 |
Why?
| | Travel | 1 | 2008 | 122 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2014 | 2765 | 0.020 |
Why?
| | Cytokines | 1 | 2015 | 1994 | 0.020 |
Why?
| | Gangrene | 1 | 2007 | 10 | 0.020 |
Why?
| | Bed Rest | 1 | 2007 | 14 | 0.020 |
Why?
| | Salmeterol Xinafoate | 1 | 2007 | 41 | 0.020 |
Why?
| | Nifedipine | 1 | 2007 | 28 | 0.020 |
Why?
| | Sildenafil Citrate | 1 | 2007 | 59 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2014 | 3021 | 0.020 |
Why?
| | Iliac Artery | 1 | 2007 | 54 | 0.020 |
Why?
| | Albuterol | 1 | 2007 | 103 | 0.020 |
Why?
| | Linear Models | 1 | 2008 | 816 | 0.020 |
Why?
| | Sulfones | 1 | 2007 | 108 | 0.020 |
Why?
| | Purines | 1 | 2007 | 169 | 0.020 |
Why?
| | Oxygen Consumption | 1 | 2008 | 671 | 0.020 |
Why?
| | Femoral Artery | 1 | 2007 | 170 | 0.020 |
Why?
| | Reference Values | 1 | 2007 | 780 | 0.010 |
Why?
| | Leg | 1 | 2007 | 237 | 0.010 |
Why?
| | Heart Rate | 1 | 2008 | 798 | 0.010 |
Why?
| | Piperazines | 1 | 2007 | 333 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2014 | 5281 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2004 | 187 | 0.010 |
Why?
| | Logistic Models | 1 | 2008 | 1980 | 0.010 |
Why?
| | Radiography, Thoracic | 1 | 2004 | 164 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1412 | 0.010 |
Why?
| | Disopyramide | 1 | 1981 | 1 | 0.010 |
Why?
| | Heart Block | 1 | 1981 | 40 | 0.010 |
Why?
| | Time Factors | 1 | 2011 | 6505 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2004 | 1668 | 0.010 |
Why?
| | Israel | 1 | 1999 | 47 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1999 | 171 | 0.010 |
Why?
| | 3T3 Cells | 1 | 1998 | 151 | 0.010 |
Why?
| | HIV Infections | 1 | 2012 | 2711 | 0.010 |
Why?
| | Pyridines | 1 | 1981 | 474 | 0.010 |
Why?
| | Radiography | 1 | 1999 | 795 | 0.010 |
Why?
| | Reoperation | 1 | 1999 | 544 | 0.010 |
Why?
| | Transcriptional Activation | 1 | 1998 | 356 | 0.010 |
Why?
| | Binding Sites | 1 | 1998 | 1244 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 1998 | 2822 | 0.010 |
Why?
| | Bundle-Branch Block | 1 | 1981 | 30 | 0.000 |
Why?
| | Heart Conduction System | 1 | 1981 | 95 | 0.000 |
Why?
|
|
Gutman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|